Manchester Capital Management’s Sutro Biopharma STRO Stock Holding History

Manchester Capital Management’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,056	Closed	-$36.6K	–	1080
2023 Q3	$36.6K	Hold	1,056	–	–	0.01%	458
2023 Q2	$49.1K	Hold	1,056	–	–	0.01%	415
2023 Q1	$48.8K	Hold	1,056	–	–	0.01%	426
2022 Q4	$85.3K	Hold	1,056	–	–	0.01%	337
2022 Q3	$59K	Hold	1,056	–	–	0.01%	347
2022 Q2	$55K	Hold	1,056	–	–	0.01%	358
2022 Q1	$87K	Hold	1,056	–	–	0.01%	354
2021 Q4	$157K	Hold	1,056	–	–	0.02%	291
2021 Q3	$199K	Hold	1,056	–	–	0.03%	280
2021 Q2	$196K	Hold	1,056	–	–	0.03%	266
2021 Q1	$240K	Hold	1,056	–	–	0.04%	242
2020 Q4	$229K	Buy	+1,056	New	+$175K	0.04%	228

Other funds holding STRO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Manchester Capital Management's STRO Position: Q4 2023 in Review

Manchester Capital Management sold out of Sutro Biopharma (STRO) in Q4 2023, closing a stake of 1,056 shares — an estimated $36.6K sold.

Manchester Capital Management first reported a position in STRO in Q4 2020 and held it in 12 quarters. The position peaked at $240K in Q1 2021. 114 funds tracked by Wall St. Rank hold STRO as of Q4 2023.

Manchester Capital Management reported no remaining Sutro Biopharma position as of Q4 2023 after selling out during the quarter.
Manchester Capital Management sold 1,056 Sutro Biopharma shares in Q4 2023, an estimated $36.6K.
Manchester Capital Management first reported a position in Sutro Biopharma in Q4 2020 and held it in 12 quarters.
Manchester Capital Management's Sutro Biopharma position peaked at $240K in Q1 2021.
114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2023.

Based on Manchester Capital Management's 13F filing for Q4 2023, filed 8 Feb 2024.